Inhibition of Silencing and Accelerated Aging by Nicotinamide, a Putative Negative Regulator of Yeast Sir2 and Human SIRT1
Open accessThe DOI matches its Crossref record; 66 of the 66 references it cites were found in a registry or an index.
Abstract
The Saccharomyces cerevisiae Sir2 protein is an NAD(+)-dependent histone deacetylase that plays a critical role in transcriptional silencing, genome stability, and longevity. A human homologue of Sir2, SIRT1, regulates the activity of the p53 tumor suppressor and inhibits apoptosis. The Sir2 deacetylation reaction generates two products: O-acetyl-ADP-ribose and nicotinamide, a precursor of nicotinic acid and a form of niacin/vitamin B(3). We show here that nicotinamide strongly inhibits yeast silencing, increases rDNA recombination, and shortens replicative life span to that of a sir2 mutant. Nicotinamide abolishes silencing and leads to an eventual delocalization of Sir2 even in G(1)-arrested cells, demonstrating that silent heterochromatin requires continual Sir2 activity. We show that physiological concentrations of nicotinamide noncompetitively inhibit both Sir2 and SIRT1 in vitro. The degree of inhibition by nicotinamide (IC(50) < 50 microm) is equal to or better than the most effective known synthetic inhibitors of this class of proteins. We propose a model whereby nicotinamide inhibits deacetylation by binding to a conserved pocket adjacent to NAD(+), thereby blocking NAD(+) hydrolysis. We discuss the possibility that nicotinamide is a physiologically relevant regulator of Sir2 enzymes.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Although NAM has been shown to be effective to increase NAD+ in tissues, it also exerts an inhibitory effect on sirtuin [88] and PARPs activity [89].”
From NAD+ Precursors Nicotinamide Mononucleotide (NMN) and Nicotinamide Riboside (NR): Potential Dietary Contribution to Health (2023) · cites this paper as [88]
In the citing paper
“Deacetylation of PGC-1α is required to sequester it in the nucleus and this cellular redistribution is prevented by nicotinamide, a potent SIRT1 inhibitor [64].”
From PGC-1α in aging and anti-aging interventions (2009) · cites this paper as [64]
Citations
Cites
Genomic Expression Programs in the Response of Yeast Cells to Environmental Changes
Gasch, A. P., Spellman, P. T., Kao, C. M., Carmel-Harel, O., Eisen, M. B., Storz, G., Botstein, D., & Brown, P. O. (2000) · Molecular Biology of the Cell · doi:10.1091/mbc.11.12.4241 · Cited by 4,815
Transcriptional silencing and longevity protein Sir2 is an NAD-dependent histone deacetylase
Imai, S.-I., Armstrong, C. M., Kaeberlein, M., & Guarente, L. (2000) · Nature · doi:10.1038/35001622 · Cited by 3,510
hSIR2SIRT1 Functions as an NAD-Dependent p53 Deacetylase
Vaziri, H., Dessain, S. K., Eaton, E. N., Imai, S.-I., Frye, R. A., Pandita, T. K., Guarente, L., & Weinberg, R. A. (2001) · Cell · doi:10.1016/s0092-8674(01)00527-x · Cited by 2,659
Kaeberlein, M., McVey, M., & Guarente, L. (1999) · Genes & Development · doi:10.1101/gad.13.19.2570 · Cited by 2,253
Negative Control of p53 by Sir2α Promotes Cell Survival under Stress
Luo, J., Nikolaev, A. Y., Imai, S.-I., Chen, D., Su, F., Shiloh, A., Guarente, L., & Gu, W. (2001) · Cell · doi:10.1016/s0092-8674(01)00524-4 · Cited by 2,081
Histone deacetylases and cancer: causes and therapies
Marks, P. A., Rifkind, R. A., Richon, V. M., Breslow, R., Miller, T., & Kelly, W. K. (2001) · Nature reviews. Cancer · doi:10.1038/35106079 · Cited by 1,866
Lin, S.-J., Defossez, P.-A., & Guarente, L. (2000) · Science · doi:10.1126/science.289.5487.2126 · Cited by 1,775
Increased dosage of a sir-2 gene extends lifespan in Caenorhabditis elegans
Tissenbaum, H. A., & Guarente, L. (2001) · Nature · doi:10.1038/35065638 · Cited by 1,603
Extrachromosomal rDNA circles—a cause of aging in yeast
Sinclair, D. A., & Guarente, L. (1997) · Cell · doi:10.1016/s0092-8674(00)80493-6 · Cited by 1,500
Self-citationPosition effect at S. cerevisiae telomeres: Reversible repression of Pol II transcription
Gottschling, D. E., Aparicio, O. M., Billington, B. L., & Zakian, V. A. (1990) · Cell · doi:10.1016/0092-8674(90)90141-z · Cited by 1,345
Research works printed but not linked: 1
- Gasser, 1998, Novartis Found. Symp., 214, 114
Cited by
Items 401–500 of 1,000
French, J. B., Cen, Y., Vrablik, T. L., Xu, P., Allen, E., Hanna-Rose, W., & Sauve, A. A. (2010) · Biochemistry · doi:10.1021/bi1012518 · Cited by 57
“Specifically, nicotinamidases regulate intracellular nicotinamide concentrations, which are implicated in negative regulation of NAD+ dependent deacetylases (the sirtuins) (16,23).”
BackgroundKang, X., Jiang, L., Lan, F., Tang, Y.-Y., Zhang, P., Zou, W., Chen, Y., & Tang, X. (2021) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2021.10.002 · Cited by 59
Integration of peroxisomes into an endomembrane system that governs cellular aging
Beach, A., Burstein, M. T., Richard, V. R., Leonov, A., Levy, S., & Titorenko, V. I. (2012) · Frontiers in Physiology · doi:10.3389/fphys.2012.00283 · Cited by 63
Function of Sirtuins in Biological Tissues
Shoba, B., Lwin, Z. M., Ling, L. S., Bay, B., Yip, G. W., & Kumar, S. D. (2009) · The Anatomical Record · doi:10.1002/ar.20875 · Cited by 57
“It is a nuclear protein that is endowed with deacetylase activity (Imai et al., 2000; Bitterman et al., 2002; Fulco et al., 2003) and interacts with several transcription regulating factors.”
BackgroundMetabolic regulation of circadian clocks
Haydon, M. J., Hearn, T. J., Bell, L. J., Hannah, M. A., & Webb, A. A. R. (2013) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2013.03.007 · Cited by 66
Yeast as a model to study mitochondrial mechanisms in ageing
de Barros, M. H., da Cunha, F. M., de Oliveira, G. A., Tahara, E. B., & Kowaltowski, A. J. (2010) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2010.04.008 · Cited by 70
Explorative Study on Isoform-Selective Histone Deacetylase Inhibitors
Suzuki, T. (2009) · Chemical and Pharmaceutical Bulletin · doi:10.1248/cpb.57.897 · Cited by 63
The role of protein arginine methylation in the formation of silent chromatin
Yu, M. C., Lamming, D. W., Eskin, J. A., Sinclair, D. A., & Silver, P. A. (2006) · Genes & Development · doi:10.1101/gad.1495206 · Cited by 63
“Silencing and mitotic rDNA recombination assay The silencing assays were carried out as previously described (Bitterman et al. 2002).”
MethodSelf-citationWang, N., Zimmerman, K., Raab, R. W., McKown, R. L., Hutnik, C. M. L., Talla, V., Tyler, M. F., Lee, J. K., & Laurie, G. W. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.436584 · Cited by 60
“Enhanced acetylation could be implied by partial exhaustion of 1-methylnicotinamide (54), coenzyme A as acetyl-CoA (55), and precursor pantothenate and by the apparent utilization of spermine and spermidine.”
BackgroundLiu, M., Shan, J., Li, J., Zhang, Y., & Lin, X.-L. (2016) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2016.3437 · Cited by 59
“SIRT1 catalyzes the deacetylation of a number of proteins, generating nicotinamide (NAM) as a by‑product that negatively regulates the activity of SIRT1 (14).”
Metabolic intermediates – Cellular messengers talking to chromatin modifiers
Nieborak, A., & Schneider, R. (2018) · Molecular Metabolism · doi:10.1016/j.molmet.2018.01.007 · Cited by 61
“SIRT activity is inhibited by several exogenous small molecules (splitomicin, sirtinol, and its analogues, EX-527) and also by NADH and NAM whose availability in mammals is tightly coupled to NADþ metabolism [79,81], providing a particularly relevant link with metabolism.”
BackgroundThe therapeutic uses of chromatin-modifying agents
Mai, A. (2007) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.11.6.835 · Cited by 61
“The first reported SIRTi were sirtinol [87], discovered through a phenotypic screening in yeast, splitomicin [88], identified from a screen of a 6000-compound library, and nicotinamide [89], all active at micromolar concentrations.”
BackgroundRole of Sirtuin 1 in metabolic regulation
Silva, J. P., & Wahlestedt, C. (2010) · Drug Discovery Today · doi:10.1016/j.drudis.2010.07.001 · Cited by 59
Mutation of OsNaPRT1 in the NAD Salvage Pathway Leads to Withered Leaf Tips in Rice
Wu, L., Ren, D., Hu, S., Li, G., Dong, G., Jiang, L., Hu, X., Ye, W., Cui, Y., Zhu, L., et al. (2016) · PLANT PHYSIOLOGY · doi:10.1104/pp.15.01898 · Cited by 58
“Moreover, altering the level of cellular nicotinamide in yeast cells, either genetically or by exogenous addition, strongly inhibits gene silencing, increases rDNA recombination, and shortens the replicative life span of the yeast to that of the sir2 mutant (Bitterman et al., 2002).”
BackgroundInfluentialThe involvement of astrocytes and kynurenine pathway in Alzheimer’s disease
Ting, K. K., Brew, B. J., & Guillemin, G. J. (2007) · Neurotoxicity Research · doi:10.1007/bf03033908 · Cited by 58
Easlon, E., Tsang, F., Dilova, I., Wang, C., Lu, S.-P., Skinner, C., & Lin, S.-J. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m607661200 · Cited by 53
Involvement of p53 in the cytotoxic activity of the NAMPT inhibitor FK866 in myeloid leukemic cells
Thakur, B. K., Dittrich, T., Chandra, P., Becker, A., Kuehnau, W., Klusmann, J., Reinhardt, D., & Welte, K. (2013) · International Journal of Cancer · doi:10.1002/ijc.27726 · Cited by 53
“Intriguingly, the specificity of NA on SIRT1 is quite unclear due to its dual ability to either activate or inhibit SIRT1, depending on the dose and context.(45,47) Despite its use in the clinical trials as a therapy for cancers,(48) further detailed investigation of its effects at molecular level is required.”
BackgroundNicotinamide Phosphoribosyl Transferase (Nampt) Is Required for De Novo Lipogenesis in Tumor Cells
Bowlby, S. C., Thomas, M. J., D’Agostino, R. B., & Kridel, S. J. (2012) · PLoS ONE · doi:10.1371/journal.pone.0040195 · Cited by 61
Sideri, T., Rallis, C., Bitton, D. A., Lages, B. M., Suo, F., Rodríguez-López, M., Du, L.-L., & Bähler, J. (2015) · G3 Genes|Genomes|Genetics · doi:10.1534/g3.114.014415 · Cited by 55
“Deletion of tif213, encoding a subunit of the translation initiation factor eIF2, results in extended lifespan in our screen, similar to budding yeast mutants deficient in translation initiation activities (Bitterman et al. 2002).”
BackgroundArenas, A., Chen, J., Kuang, L., Barnett, K. R., Kasarskis, E. J., Gál, J., & Zhu, H. (2020) · Human Molecular Genetics · doi:10.1093/hmg/ddaa159 · Cited by 56
“To identify which family of lysine deacetylases deacetylates FUS, we treated N2A cells with two DACis for 24 h: nicotinamide that inhibits SIRTs (52), and TSA that inhibits a broad range of HDACs (53).”
BackgroundInfluentialSirtuins: double players in Huntington's disease
Naia, L., & Rego, A. C. (2015) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2015.07.003 · Cited by 57
Histone Deacetylase Enzymes as Potential Drug Targets in Cancer and Parasitic Diseases
Ouaïssi, M., & Ouaissi, A. (2006) · BioMed Research International · doi:10.1155/jbb/2006/13474 · Cited by 63
“Moreover, recent investigations have shown that SIRT1, a member of class III deacetylases, represses NF-κB function by deacetylating the RelA/p65 lysine 310 [52], regulating therefore its antiapoptotic activity.”
BackgroundInfluentialKadyrova, L. Y., Mertz, T. M., Zhang, Y., Northam, M. R., Sheng, Z., Lobachev, K. S., Shcherbakova, P. V., & Kadyrov, F. A. (2013) · PLoS Genetics · doi:10.1371/journal.pgen.1003899 · Cited by 56
“We showed that exposure of yeast strains to 50-mM NAM, a specific inhibitor of the NADdependent histone deacetylases [62], produces a strong 30-fold increase in the CAN1 mutation rate (Figure 1A).”
BackgroundA fluorogenic assay for screening Sirt6 modulators
Hu, J., He, B., Bhargava, S., & Lin, H. (2013) · Organic & Biomolecular Chemistry · doi:10.1039/c3ob41138a · Cited by 58
Wang, F., Yao, S., & Xia, H. (2020) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2020.110601 · Cited by 55
CD38 in the age of COVID-19: a medical perspective
Horenstein, A. L., Faini, A. C., & Malavasi, F. (2021) · Physiological Reviews · doi:10.1152/physrev.00046.2020 · Cited by 59
The Caenorhabditis elegans nicotinamidase PNC-1 enhances survival
van der Horst, A., Schavemaker, J. M., Berkel, W. P.-V., & Burgering, B. M. T. (2007) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2007.01.004 · Cited by 53
French, J. B., Cen, Y., & Sauve, A. A. (2008) · Biochemistry · doi:10.1021/bi800767t · Cited by 60
“Sirtuin deacetylation reactions are inhibited by the general sirtuin inhibitor nicotinamide, which is a product of sirtuin deacetylation chemistry (11, 12, 29, 30).”
Some organotin compounds enhance histone acetyltransferase activity
Osada, S., Nishikawa, J., Nakanishi, T., Tanaka, K., & Nishihara, T. (2004) · Toxicology Letters · doi:10.1016/j.toxlet.2004.10.009 · Cited by 56
Vendrell, A., Martínez-Pastor, M., González‐Novo, A., Pascual‐Ahuir, A., Sinclair, D. A., Proft, M., & Posas, F. (2011) · EMBO Reports · doi:10.1038/embor.2011.154 · Cited by 52
“Expression of PNC1 is induced in response to osmostress by Msn2 and Msn4 (Posas et al, 2000; Causton et al, 2001), and the role of Msn2 and Msn4 in cell longevity is mediated by PNC1, an activator of Sir2 (Bitterman et al, 2002; Anderson et al, 2003; Gallo et al, 2004; Medvedik et al, 2007).”
BackgroundMethodSelf-citationComparative and pharmacophore model for deacetylase SIRT1
Huhtiniemi, T., Wittekindt, C., Laitinen, T., Leppänen, J., Salminen, A., Poso, A., & Lahtela-Kakkonen, M. K. (2006) · Journal of Computer-Aided Molecular Design · doi:10.1007/s10822-006-9084-9 · Cited by 56
Li, J., Dou, X., Li, S., Zhang, X., Zeng, Y., & Song, Z. (2015) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2015.09.003 · Cited by 52
“It is the general product of Sirt1catalyzed deacetylation reactions and was reported to inhibit Sirt1 enzyme activity with either competitive or noncompetitive mechanism [27-29].”
BackgroundThe sirtuins: Markers of metabolic health
Covington, J. D., & Bajpeyi, S. (2015) · Molecular Nutrition & Food Research · doi:10.1002/mnfr.201500340 · Cited by 54
Quantitation of NAD+ biosynthesis from the salvage pathway in Saccharomyces cerevisiae
Sporty, J. L., Lin, S.-J., Kato, M., Ognibene, T. J., Stewart, B. J., Turteltaub, K. W., & Bench, G. (2009) · Yeast · doi:10.1002/yea.1671 · Cited by 51
“It has also been suggested that nicotinamide, which is generated during the deacetylation reaction and can inhibit Sir2p in vitro, is a negative regulator of Sir2p in vivo (Bitterman et al., 2002).”
BackgroundZhou, L., Zhang, S., Bolor-Erdene, E., Wang, L., Ding, T., & Mei, Y. (2020) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2020/1974265 · Cited by 56
“and potentially contributes to the ability of cancer cells to resist oxidative stress [19].”
NAD and axon degeneration: From the Wlds gene to neurochemistry
Wang, J., & He, Z. (2009) · Cell Adhesion & Migration · doi:10.4161/cam.3.1.7483 · Cited by 56
Roles of sirtuin family members in chronic obstructive pulmonary disease
Zhang, X.-Y., Li, W., Zhang, J., Li, C., Zhang, J., & Lv, X. (2022) · Respiratory Research · doi:10.1186/s12931-022-01986-y · Cited by 53
“Sirtuins regulate cell metabolism, cell cycle, differentiation, autophagy/apoptosis, and senescence [5].”
BackgroundBi, J., Li, H., Ye, S. Q., & Ding, S. (2012) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2011.07566.x · Cited by 51
Zhang, Y., Wang, J., Chen, G., Fan, D., & Deng, M. (2010) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2010.12.014 · Cited by 52
Interference between PARPs and SIRT1: a novel approach to healthy ageing?
Cantó, C., & Auwerx, J. (2011) · Aging · doi:10.18632/aging.100326 · Cited by 50
“Furthermore of relevance is that the breakdown product of both the SIRT1 and PARP reactions, NAM, is an allosteric inhibitor of SIRT1 activity [13].”
BackgroundNiacin Inhibits Apoptosis and Rescues Premature Ovarian Failure
Wang, S., Sun, M., Yu, L., Wang, Y., Yao, Y., & Wang, D. (2018) · Cellular Physiology and Biochemistry · doi:10.1159/000495051 · Cited by 51
The NAD+/NADH redox state in astrocytes: Independent control of the NAD+ and NADH content
Wilhelm, F., & Hirrlinger, J. (2011) · Journal of Neuroscience Research · doi:10.1002/jnr.22638 · Cited by 52
“NAM is also a potent inhibitor of NAD(1)-degrading pathways (Bitterman et al., 2002).”
BackgroundPharmacology and Potential Implications of Nicotinamide Adenine Dinucleotide Precursors
She, J., Sheng, R., & Qin, Z. (2021) · Aging and Disease · doi:10.14336/ad.2021.0523 · Cited by 53
“Several studies have shown that the activities of PARP, sirtuin, and CD38 are inhibited at high doses of NAM [162].”
BackgroundWang, T., Cui, H., MA, N., & Jiang, Y. (2013) · Oncology Letters · doi:10.3892/ol.2013.1400 · Cited by 53
The role of SirT1 in muscle mitochondrial turnover
Menzies, K. J., & Hood, D. A. (2011) · Mitochondrion · doi:10.1016/j.mito.2011.03.001 · Cited by 51
Profiling Deacetylase Activities in Cell Lysates with Peptide Arrays and SAMDI Mass Spectrometry
Kuo, H.-Y., DeLuca, T. A., Miller, W. M., & Mrksich, M. (2013) · Analytical Chemistry · doi:10.1021/ac402614x · Cited by 51
Higashitsuji, H., Higashitsuji, H., Masuda, T., Liu, Y., Itoh, K., & Fujita, J. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m609751200 · Cited by 50
Regulation of SV40 large T-antigen stability by reversible acetylation
Shimazu, T., Komatsu, Y., Nakayama, K. I., Fukazawa, H., Horinouchi, S., & Yoshida, M. (2006) · Oncogene · doi:10.1038/sj.onc.1209731 · Cited by 49
“On the other hand, Sir2-related class III HDACs are resistant to TSA and are inhibited by nicotinamide (NA), the by-product of NAD-dependent deacetylation (Imai et al., 2000; Bitterman et al., 2002).”
BackgroundVrablik, T. L., Huang, L., Lange, S. E., & Hanna‐Rose, W. (2009) · Development · doi:10.1242/dev.028431 · Cited by 53
“It is currently debated whether Pnc1 regulation of NAD+ or NAM levels is most relevant to activation of sirtuins (Bitterman et al., 2002; Gallo et al., 2004; Lin et al., 2000; Lin et al., 2004).”
BackgroundLogan, R. W., Parekh, P. K., Kaplan, G. N., Becker-Krail, D. D., Williams, W. P., Yamaguchi, S., Yoshino, J., Shelton, M. A., Zhu, X., Zhang, H., et al. (2019) · Molecular Psychiatry · doi:10.1038/s41380-018-0061-1 · Cited by 48
“NAM is a byproduct of NAD+ metabolism and part of the biosynthesis pathway regulating SIRT1 [89].”
Characterization of Trypanosoma cruzi Sirtuins as Possible Drug Targets for Chagas Disease
Moretti, N. S., Augusto, L. D. S., Clemente, T. M., Antunes, R. P. P., Yoshida, N., Torrecilhas, A. C., Cano, M. I. N., & Schenkman, S. (2015) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.04694-14 · Cited by 52
“Nicotinamide, an amide of nicotinic acid, has been described as the classical sirtuin inhibitor (37, 38).”
BackgroundSirtuins, Bioageing, and Cancer
McGuinness, D. H., McGuinness, D. H., McCaul, J. A., & Shiels, P. G. (2011) · Journal of Aging Research · doi:10.4061/2011/235754 · Cited by 56
“This is supported by the observation that the Nicotinamide (NAM) product site can be occupied in the presence of substrates and reaction intermediates [22, 23].”
BackgroundSirtuin-1 and HIV-1: An Overview
Pinzone, M. R., Cacopardo, B. S., Condorelli, F., Rosa, M. D., & Nunnari, G. (2013) · Current Drug Targets · doi:10.2174/1389450111314060005 · Cited by 50
Aragonès, G., Suárez, M., Ardid‐Ruiz, A., Vinaixa, M., Rodriguez, M. A., Correig, X., Arola, L., & Bladé, C. (2016) · Scientific Reports · doi:10.1038/srep24977 · Cited by 52
Hisahara, S., Chiba, S., Matsumoto, H., & Horio, Y. (2005) · Journal of Pharmacological Sciences · doi:10.1254/jphs.fmj05001x2 · Cited by 52
Maiese, K. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1273570 · Cited by 54
McCormack, S., Polyak, E., Ostrovsky, J., Dingley, S. D., Rao, M., Kwon, Y. J., Xiao, R., Zhang, Z., Nakamaru-Ogiso, E., & Falk, M. J. (2015) · Mitochondrion · doi:10.1016/j.mito.2015.02.005 · Cited by 45
“Recognition of these secondary metabolite deficiencies in RC disease has important therapeutic implications, as we were able to show that treating the RC deficient patient cells for 24 hours with an NAD+ precursor, nicotinic acid, restored cellular NAD+ and NADH concentrations and improved total cellular mitochondrial…”
BackgroundInfluentialMitochondria as a therapeutic target in Alzheimer's disease
Wang, J., & Chen, G.-J. (2016) · Genes & Diseases · doi:10.1016/j.gendis.2016.05.001 · Cited by 44
“SIRT1 deacetylates PGC1a and promotes nuclear transfer.(38) AMPK is a sensor of AMP/ATP ratio.”
BackgroundStarai, V. J., Takahashi, H., Boeke, J. D., & Escalante-Semerena, J. (2004) · Current Opinion in Microbiology · doi:10.1016/j.mib.2004.02.005 · Cited by 53
Ocampo, A., Liu, J., & Barrientos, A. (2013) · Human Molecular Genetics · doi:10.1093/hmg/ddt016 · Cited by 46
Chromatin Modifications as Targets for New Anticancer Drugs
Schäfer, S., & Jung, M. (2005) · Archiv der Pharmazie · doi:10.1002/ardp.200500984 · Cited by 59
Campagna, R., Pozzi, V., Sartini, D., Salvolini, E., Brisigotti, V., Molinelli, E., Campanati, A., Offidani, A., & Emanuelli, M. (2021) · Cancers · doi:10.3390/cancers13194943 · Cited by 46
Novel Avenues of Drug Discovery and Biomarkers for Diabetes Mellitus
Maiese, K., Chong, Z. Z., Shang, Y. C., & Hou, J. (2011) · The Journal of Clinical Pharmacology · doi:10.1177/0091270010362904 · Cited by 46
“Physiological concentrations of nicotinamide noncompetitively inhibit Sir2, suggesting that nicotinamide is a physiologically relevant regulator of Sir2 enzymes.(356) Interestingly, nicotinamidase expression, which reduces nicotinamide concentrations, prevents both apoptotic late DNA degradation and early PS exposure…”
BackgroundGiammona, L. M., Panuganti, S., Kemper, J. M., Apostolidis, P. A., Lindsey, S. C., Papoutsakis, E. T., & Miller, W. M. (2009) · Experimental Hematology · doi:10.1016/j.exphem.2009.08.004 · Cited by 49
“Deacetylation by the nuclear protein SIRT1 [42] regulates the activity of proteins associated with DNA repair, apoptosis, and cell cycle regulation including NBS1, p53, FOXO3a, RelA/p65 (nuclear factor kB), and Ku70 [15,54,60–63].”
Regulatory Effects of NAD + Metabolic Pathways on Sirtuin Activity
Zhang, N., & Sauve, A. A. (2018) · Progress in molecular biology and translational science · doi:10.1016/bs.pmbts.2017.11.012 · Cited by 50
“that binds to the C-pocket of sirtuins and acts by base exchange to inhibit sirtuin activity.(149) NAM is probably the most universal and biologically”
Identification of a cell-active non-peptide sirtuin inhibitor containing N-thioacetyl lysine
Suzuki, T., Asaba, T., Imai, E., Tsumoto, H., Nakagawa, H., & Miyata, N. (2009) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2009.08.028 · Cited by 45
Chou, W., Chen, K., Wang, Y., Wang, J., Liang, C.-L., & Juo, S. H. (2013) · Toxicology in Vitro · doi:10.1016/j.tiv.2013.05.002 · Cited by 45
Akieda‐Asai, S., Zaima, N., Ikegami, K., Kahyo, T., Yao, I., Hatanaka, T., Iemura, S.-I., Sugiyama, R., Yokozeki, T., Eishi, Y., et al. (2010) · PLoS ONE · doi:10.1371/journal.pone.0011755 · Cited by 49
“(NAM), a SIRT1 inhibitor [35], increased the lysine acetylation of PIP5Kc, but did not alter the acetylation levels of PIP5Ka and PIP5Kb (Fig.”
BackgroundEmploying New Cellular Therapeutic Targets for Alzheimers Disease: A Change for the Better?
Chong, Z., Li, F., & Maiese, K. (2005) · Current Neurovascular Research · doi:10.2174/1567202052773508 · Cited by 44
Yao, J., Zhang, X., Zhang, Y.-Z., Li, J.-H., Zhao, D., Gao, B., Zhou, H., Gao, S., & Zhang, L. (2019) · Investigational New Drugs · doi:10.1007/s10637-019-00767-7 · Cited by 44
Mitochondrial Metabolism Modulation: A New Therapeutic Approach for Parkinsons Disease
Arduino, D., Esteves, A., Oliveira, C., & Cardoso, S. (2010) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/187152710790966687 · Cited by 44
“Given the subcellular sorting of SIRTs and their dependence on NAD and the cellular NAD/NADH ratio, the absolute levels of NAD, NADH, or NAM, or a combination of these variables, SIRTs may be considered extremely versatile energy sensors for cellular metabolic status [36-40].”
Urbán, V. S., Ceglédi, A., & Mikala, G. (2022) · GeroScience · doi:10.1007/s11357-022-00698-x · Cited by 45
Calorie restriction effects on silencing and recombination at the yeast rDNA
Smith Jr, D. L., Li, C., Matecic, M., Maqani, N., Bryk, M., & Smith, J. S. (2009) · Aging Cell · doi:10.1111/j.1474-9726.2009.00516.x · Cited by 43
“NAM is a strong noncompetitive inhibitor of Sirtuins that is also a byproduct of the NAD+-dependent deacetylase reaction (Landry et al., 2000a; Tanny & Moazed, 2001; Bitterman et al., 2002).”
BackgroundThe protective effects of resveratrol on Schwann cells with toxicity induced by ethanol in vitro
Yuan, H., Zhang, J., Liu, H., & Li, Z. (2013) · Neurochemistry International · doi:10.1016/j.neuint.2013.05.011 · Cited by 43
Aging and anti-aging: Unexpected side effects of everyday medication through sirtuin1 modulation
Engel, N., & Mahlknecht, U. (2008) · International Journal of Molecular Medicine · doi:10.3892/ijmm.21.2.223 · Cited by 43
Hocher, A., Ruault, M., Kaferle, P., Descrimes, M., Garnier, M., Morillon, A., & Taddei, A. (2018) · Genome Research · doi:10.1101/gr.236554.118 · Cited by 46
“amide (NAM), which inhibits Sir2 activity and thus silencing (Bitterman et al. 2002).”
BackgroundHuang, P., Riordan, S. M., Heruth, D. P., Grigoryev, D. N., Zhang, L. Q., & Ye, S. Q. (2015) · Oncotarget · doi:10.18632/oncotarget.3580 · Cited by 45
“These response pathways include members of the sirtuins, a family of protein deactylases [10].”
Xu, C., Bai, B., Fan, P., Cai, Y., Huang, B., Law, I. K. M., Liu, L., Xu, A., Tung, C., Li, X., et al. (2013) · Europe PMC (PubMed Central) · Cited by 53
Modification of DBC1 by SUMO2/3 is crucial for p53-mediated apoptosis in response to DNA damage
Park, J., Lee, S. W., Yang, S. W., Yoo, H. M., Park, J. M., Seong, M. W., Ka, S. H., Oh, K. H., Jeon, Y. J., & Chung, C. H. (2014) · Nature Communications · doi:10.1038/ncomms6483 · Cited by 44
Deng, X., Cheng, J., Zhang, Y., Li, N., & Chen, L. (2009) · Acta Diabetologica · doi:10.1007/s00592-009-0159-7 · Cited by 45
“Research on Saccharomyces cerevisiae showed that the small molecular protein encoded by Sir2 gene, which plays a key role in CR effects may mediate the silence of chromatin, telomere, rDNA and the repairing of DNA, which accordingly maintains the stability of the genome and increases life span [19, 20].”
BackgroundAgerholm, M., Dall, M., Jensen, B. A. H., Prats, C., Madsen, S., Basse, A. L., Graae, A.-S., Risis, S., Goldenbaum, J., Quistorff, B., et al. (2018) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00213.2017 · Cited by 43
“Nicotinamide inhibits sirtuin activity (3, 6), and resynthesis of NAD may be critical for maintaining sirtuin activity (54) and, thereby, mitochondrial adaptability and function.”
BackgroundNAD+ Metabolism, Metabolic Stress, and Infection
Groth, B., Venkatakrishnan, P., & Lin, S.-J. (2021) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2021.686412 · Cited by 46
Resveratrol inhibits PDGF receptor mitogenic signaling in mesangial cells: role of PTP1B
Venkatesan, B. A., Ghosh‐Choudhury, N., Das, F., Mahimainathan, L., Kamat, A., Kasinath, B. S., Abboud, H. E., & Choudhury, G. G. (2008) · The FASEB Journal · doi:10.1096/fj.08-109488 · Cited by 47
“We examined this hypothesis using NAM, a SIRT1 inhibitor (57, 58).”
MethodWilliams, A. C., Hill, L. J., & Ramsden, D. B. (2012) · Current Gerontology and Geriatrics Research · doi:10.1155/2012/302875 · Cited by 43
Cheng, Y., Kao, C.-L., Ma, H.-I., Hung, C., Wang, C.-T., Liu, D.-H., Chen, P.-Y., & Tsai, K. (2015) · The Journal of Biochemistry · doi:10.1093/jb/mvv041 · Cited by 45
Lysine Deacetylase (KDAC) Regulatory Pathways: an Alternative Approach to Selective Modulation
Dyke, M. W. V. (2014) · ChemMedChem · doi:10.1002/cmdc.201300444 · Cited by 49
Zheng, T., & Lü, Y. (2015) · Current Eye Research · doi:10.3109/02713683.2015.1093641 · Cited by 45
Quantitative Assays for Characterization of the Sir2 Family of NAD+-Dependent Deacetylases
Borra, M. T., & Denu, J. M. (2003) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/s0076-6879(03)76011-x · Cited by 49
Targeting histone deacetylases for heart failure
Bush, E. W., & McKinsey, T. A. (2009) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728220902939161 · Cited by 43
“In contrast, suppression of endogenous SIRT1 activity with a small molecule inhibitor of class III HDACs, sirtinol [179], or nicotinamide, which is a product of the deacetylase reaction that is a feedback inhibitor of the enzyme [180], results in exaggerated apoptosis [177].”
NAD+ Precursors: A Questionable Redundancy
Cantó, C. (2022) · Metabolites · doi:10.3390/metabo12070630 · Cited by 44
Aspirin attenuates vinorelbine-induced endothelial inflammation via modulating SIRT1/AMPK axis
Tsai, K., Huang, P., Kao, C.-L., Leu, H., Cheng, Y., Liao, Y., Yang, Y.-P., Chien, Y., Wang, C., Hsiao, C.-Y., et al. (2013) · Biochemical Pharmacology · doi:10.1016/j.bcp.2013.12.005 · Cited by 43
García-Aguilar, A., Guillén, C., Nellist, M. D., Bartolomé, A., & Benito, M. (2016) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2016.08.006 · Cited by 44
A systems-approach to NAD+ restoration
Conlon, N. J., & Ford, D. (2022) · Biochemical Pharmacology · doi:10.1016/j.bcp.2022.114946 · Cited by 47
Impairment of p53 acetylation by EWS-Fli1 chimeric protein in Ewing Family Tumors
Li, Y., Li, X., Fan, G.-Y., Fukushi, J., Matsumoto, Y., Iwamoto, Y., & Zhu, Y. (2012) · Cancer Letters · doi:10.1016/j.canlet.2012.01.018 · Cited by 46
Orlandi, I., Alberghina, L., & Vai, M. (2020) · Biomolecules · doi:10.3390/biom10040604 · Cited by 42
“NAM supplementation (5 mM) to yeast growth media inhibits Sir2 activity resulting in a phenocopy of SIR2 inactivation—NAM-treated cells display a reduction in silencing, an increased recombination at the rDNA locus and a short RLS similar to that of a sir2 null mutant [47].”
BackgroundSIRT1 and gynecological malignancies (Review)
Chen, J., Chen, H., & Pan, L. (2021) · Oncology Reports · doi:10.3892/or.2021.7994 · Cited by 44
“acetyl moiety of the substrate, and releasing nicotinamide (NAM) and 2'‐O‐acetyl‐adenosine diphosphate‐ribose (O‐AcADPR) (10,11).”
BackgroundVisceral adipose tissue visfatin in nonalcoholic fatty liver disease
Gaddipati, R., Mitnala, S., Padaki, N., Mukherjee, R. M., Sekaran, A., Jayaraj-Mansard, M., Rabella, P., Rao-Guduru, V., & Reddy-Duwuru, N. (2010) · Annals of Hepatology · doi:10.1016/s1665-2681(19)31635-7 · Cited by 39
The emergence of the nicotinamide riboside kinases in the regulation of NAD+ metabolism
Fletcher, R. S., & Lavery, G. G. (2018) · Journal of Molecular Endocrinology · doi:10.1530/jme-18-0085 · Cited by 38
Immunotherapy of COVID-19 with poly (ADP-ribose) polymerase inhibitors: starting with nicotinamide
Badawy, A. A. ‐. (2020) · Bioscience Reports · doi:10.1042/bsr20202856 · Cited by 41
Choudhry, S. K., Singh, R., Williams, C., & van der Klei, I. J. (2015) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2015.10.017 · Cited by 43
“It has been suggested that this is the result of Pnc1-mediated nicotinamide depletion in the nucleus, which activates the histone deacetylase Sir2, resulting in silencing of pro-ageing genes [1,10].”
Background
Metadata
- Authors
- Bitterman, K. J., Anderson, R. M., Cohen, H. Y., Latorre-Esteves, M., & Sinclair, D. A.
- Affiliations
- Harvard University (US)
- Corresponding author
- Sinclair, David A.
- Venue
- Journal of Biological Chemistry
- Publisher
- Elsevier BV
- Published
- 2002-11
- Volume
- 277
- Issue
- 47
- Pages
- 45099-45107
- ISSN
- 0021-9258 (ISSN-L)
- OpenAlex
- W2167990179
- Cited by
- 1,002
- References
- 66
- Citations by year
- 2026: 16 · 2025: 24 · 2024: 32 · 2023: 33 · 2022: 36 · 2021: 41 · 2020: 38 · 2019: 39 · 2018: 47 · 2017: 43 · 2016: 43 · 2015: 58 · 2014: 40 · 2013: 58 · 2012: 56
- FWCI
- 21.51
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- creativecommons.org/licenses/by/4.0/ (vor, 6554 d)
- Locations
- Journal of Biological Chemistry (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- National Institute on Aging (AG11972-01)
- Topics
- Health Sciences › Medicine › Geriatrics and Gerontology › Sirtuins and Resveratrol in Medicine
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Nuclear Structure and Function
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Histone Deacetylase Inhibitors Research
- Keywords
- nicotinamide, Sir2, SIRT1, transcriptional silencing, heterochromatin, replicative lifespan, aging, NAD+ hydrolysis, enzyme inhibition, p53, apoptosis, histone deacetylation
- MeSH terms
- Aging, DNA, Ribosomal, Genes, Fungal, Histone Deacetylases, Humans, Life Expectancy, Luminescent Proteins, Models, Biological, Niacinamide, Recombinant Fusion Proteins, Recombination, Genetic, Saccharomyces cerevisiae, Molecular Structure, Telomere, Gene Silencing, Sirtuins, Silent Information Regulator Proteins, Saccharomyces cerevisiae, Green Fluorescent Proteins, Sirtuin 1, Sirtuin 2
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.